Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial

Luca Faconti, Charlotte Elizabeth Mills, Virginia Govoni, Haotian Gu, Steven Morant, Benju Jiang, J. Kennedy Cruickshank, Andrew James Webb (Lead / Corresponding author)

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims: The aims of the present study were to explore whether a long-term intervention with dietary nitrate [(NO 3 ), a potential tolerance-free source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). Methods: A subsample of participants in our double-blind, randomized, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had transthoracic cardiac ultrasounds at baseline (n = 105), and at 3 months and 6 months (n = 87) after the start of the intervention. Analysis was by modified intent-to-treat. Results: Nitrate-containing juice (n = 40) decreased left ventricular (LV) end-diastolic volume {−6.3 [95% confidence interval (CI) –11.1, –1.6] ml} and end-systolic volume [−3.2 (95% CI −5.9, –0.5) ml], and increased end-diastolic mass/volume ratio [+0.04 (95% CI 0.00, 0.07)], relative to placebo juice (n = 47). Spironolactone (n = 44) reduced relative wall thickness compared with doxazosin (n = 43) [−0.01 (95% CI −0.02, –0.00)]. Although spironolactone reduced LV mass index relative to baseline [−1.48 (95% CI −2.08, –0.88) g m –2.7], there was no difference vs. doxazosin [−0.85 (95% CI −1.76, 0.05) g m –2.7]. Spironolactone also decreased the E/A ratio [−0.12 (95% CI −0.19, –0.04)] and increased S′ (a tissue-Doppler systolic function index) by 0.52 (95% CI 0.05, 1.0) cm s –1. BP did not differ between the juices, or between the drugs. Conclusions: Six months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterized in preclinical models of heart failure. Spironolactone's effects on cardiac remodelling and systolic–diastolic function, although confirmatory, were independent of BP.

Original languageEnglish
Pages (from-to)169-180
Number of pages12
JournalBritish Journal of Clinical Pharmacology
Volume85
Issue number1
Early online date7 Oct 2018
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Spironolactone
Nitrates
Type 2 Diabetes Mellitus
Randomized Controlled Trials
Confidence Intervals
Hypertension
Doxazosin
Blood Pressure
Heart Failure
Placebos
Aldosterone
Stroke Volume
Nitric Oxide

Keywords

  • beetroot juice
  • cardiac remodelling
  • dietary nitrate
  • echocardiography
  • nitrate–nitrite–NO pathway
  • type 2 diabetes

Cite this

Faconti, Luca ; Mills, Charlotte Elizabeth ; Govoni, Virginia ; Gu, Haotian ; Morant, Steven ; Jiang, Benju ; Cruickshank, J. Kennedy ; Webb, Andrew James. / Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial. In: British Journal of Clinical Pharmacology. 2019 ; Vol. 85, No. 1. pp. 169-180.
@article{597ace0c2e83430398f8bfabe005c035,
title = "Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial",
abstract = "Aims: The aims of the present study were to explore whether a long-term intervention with dietary nitrate [(NO 3 −), a potential tolerance-free source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). Methods: A subsample of participants in our double-blind, randomized, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had transthoracic cardiac ultrasounds at baseline (n = 105), and at 3 months and 6 months (n = 87) after the start of the intervention. Analysis was by modified intent-to-treat. Results: Nitrate-containing juice (n = 40) decreased left ventricular (LV) end-diastolic volume {−6.3 [95{\%} confidence interval (CI) –11.1, –1.6] ml} and end-systolic volume [−3.2 (95{\%} CI −5.9, –0.5) ml], and increased end-diastolic mass/volume ratio [+0.04 (95{\%} CI 0.00, 0.07)], relative to placebo juice (n = 47). Spironolactone (n = 44) reduced relative wall thickness compared with doxazosin (n = 43) [−0.01 (95{\%} CI −0.02, –0.00)]. Although spironolactone reduced LV mass index relative to baseline [−1.48 (95{\%} CI −2.08, –0.88) g m –2.7], there was no difference vs. doxazosin [−0.85 (95{\%} CI −1.76, 0.05) g m –2.7]. Spironolactone also decreased the E/A ratio [−0.12 (95{\%} CI −0.19, –0.04)] and increased S′ (a tissue-Doppler systolic function index) by 0.52 (95{\%} CI 0.05, 1.0) cm s –1. BP did not differ between the juices, or between the drugs. Conclusions: Six months' dietary nitrate decreased LV volumes ~5{\%}, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterized in preclinical models of heart failure. Spironolactone's effects on cardiac remodelling and systolic–diastolic function, although confirmatory, were independent of BP.",
keywords = "beetroot juice, cardiac remodelling, dietary nitrate, echocardiography, nitrate–nitrite–NO pathway, type 2 diabetes",
author = "Luca Faconti and Mills, {Charlotte Elizabeth} and Virginia Govoni and Haotian Gu and Steven Morant and Benju Jiang and Cruickshank, {J. Kennedy} and Webb, {Andrew James}",
note = "This article is protected by copyright. All rights reserved.",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bcp.13783",
language = "English",
volume = "85",
pages = "169--180",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley",
number = "1",

}

Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial. / Faconti, Luca; Mills, Charlotte Elizabeth; Govoni, Virginia; Gu, Haotian; Morant, Steven; Jiang, Benju; Cruickshank, J. Kennedy; Webb, Andrew James (Lead / Corresponding author).

In: British Journal of Clinical Pharmacology, Vol. 85, No. 1, 01.01.2019, p. 169-180.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial

AU - Faconti, Luca

AU - Mills, Charlotte Elizabeth

AU - Govoni, Virginia

AU - Gu, Haotian

AU - Morant, Steven

AU - Jiang, Benju

AU - Cruickshank, J. Kennedy

AU - Webb, Andrew James

N1 - This article is protected by copyright. All rights reserved.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aims: The aims of the present study were to explore whether a long-term intervention with dietary nitrate [(NO 3 −), a potential tolerance-free source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). Methods: A subsample of participants in our double-blind, randomized, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had transthoracic cardiac ultrasounds at baseline (n = 105), and at 3 months and 6 months (n = 87) after the start of the intervention. Analysis was by modified intent-to-treat. Results: Nitrate-containing juice (n = 40) decreased left ventricular (LV) end-diastolic volume {−6.3 [95% confidence interval (CI) –11.1, –1.6] ml} and end-systolic volume [−3.2 (95% CI −5.9, –0.5) ml], and increased end-diastolic mass/volume ratio [+0.04 (95% CI 0.00, 0.07)], relative to placebo juice (n = 47). Spironolactone (n = 44) reduced relative wall thickness compared with doxazosin (n = 43) [−0.01 (95% CI −0.02, –0.00)]. Although spironolactone reduced LV mass index relative to baseline [−1.48 (95% CI −2.08, –0.88) g m –2.7], there was no difference vs. doxazosin [−0.85 (95% CI −1.76, 0.05) g m –2.7]. Spironolactone also decreased the E/A ratio [−0.12 (95% CI −0.19, –0.04)] and increased S′ (a tissue-Doppler systolic function index) by 0.52 (95% CI 0.05, 1.0) cm s –1. BP did not differ between the juices, or between the drugs. Conclusions: Six months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterized in preclinical models of heart failure. Spironolactone's effects on cardiac remodelling and systolic–diastolic function, although confirmatory, were independent of BP.

AB - Aims: The aims of the present study were to explore whether a long-term intervention with dietary nitrate [(NO 3 −), a potential tolerance-free source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). Methods: A subsample of participants in our double-blind, randomized, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had transthoracic cardiac ultrasounds at baseline (n = 105), and at 3 months and 6 months (n = 87) after the start of the intervention. Analysis was by modified intent-to-treat. Results: Nitrate-containing juice (n = 40) decreased left ventricular (LV) end-diastolic volume {−6.3 [95% confidence interval (CI) –11.1, –1.6] ml} and end-systolic volume [−3.2 (95% CI −5.9, –0.5) ml], and increased end-diastolic mass/volume ratio [+0.04 (95% CI 0.00, 0.07)], relative to placebo juice (n = 47). Spironolactone (n = 44) reduced relative wall thickness compared with doxazosin (n = 43) [−0.01 (95% CI −0.02, –0.00)]. Although spironolactone reduced LV mass index relative to baseline [−1.48 (95% CI −2.08, –0.88) g m –2.7], there was no difference vs. doxazosin [−0.85 (95% CI −1.76, 0.05) g m –2.7]. Spironolactone also decreased the E/A ratio [−0.12 (95% CI −0.19, –0.04)] and increased S′ (a tissue-Doppler systolic function index) by 0.52 (95% CI 0.05, 1.0) cm s –1. BP did not differ between the juices, or between the drugs. Conclusions: Six months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterized in preclinical models of heart failure. Spironolactone's effects on cardiac remodelling and systolic–diastolic function, although confirmatory, were independent of BP.

KW - beetroot juice

KW - cardiac remodelling

KW - dietary nitrate

KW - echocardiography

KW - nitrate–nitrite–NO pathway

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85056382174&partnerID=8YFLogxK

U2 - 10.1111/bcp.13783

DO - 10.1111/bcp.13783

M3 - Article

VL - 85

SP - 169

EP - 180

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 1

ER -